Does the media refer more to YARW or NEUP?

In the previous week, Yarrow Bioscience had 9 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 11 mentions for Yarrow Bioscience and 2 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 0.93 beat Yarrow Bioscience's score of 0.64 indicating that Neuphoria Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Yarrow Bioscience 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neuphoria Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NEUP or CTOR more profitable?

Neuphoria Therapeutics' return on equity of -76.93% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Neuphoria Therapeutics N/A -76.93% -54.76% Citius Oncology N/A -102.98% -43.49%

Do analysts rate NEUP or TELO?

Neuphoria Therapeutics presently has a consensus price target of $7.00, suggesting a potential upside of 87.67%. Given Neuphoria Therapeutics' higher probable upside, research analysts plainly believe Neuphoria Therapeutics is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuphoria Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is NEUP or TELO more profitable?

Neuphoria Therapeutics' return on equity of -76.93% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Neuphoria Therapeutics N/A -76.93% -54.76% Telomir Pharmaceuticals N/A -102.70% -90.75%

Does the media refer more to NEUP or SERA?

In the previous week, Sera Prognostics had 8 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 10 mentions for Sera Prognostics and 2 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 0.93 beat Sera Prognostics' score of 0.44 indicating that Neuphoria Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuphoria Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sera Prognostics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GANX or NEUP more profitable?

Neuphoria Therapeutics' return on equity of -76.93% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -161.59% -118.36% Neuphoria Therapeutics N/A -76.93% -54.76%

Does the media refer more to GANX or NEUP?

In the previous week, Gain Therapeutics had 1 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 3 mentions for Gain Therapeutics and 2 mentions for Neuphoria Therapeutics. Gain Therapeutics' average media sentiment score of 1.15 beat Neuphoria Therapeutics' score of 0.93 indicating that Gain Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neuphoria Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Neuphoria Therapeutics (NEUP) Competitors

$3.73 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.74 +0.01 (+0.27%)

As of 09/11/2026 04:10 PM Eastern

Compare

NEUP vs. YARW, CTOR, TELO, SERA, and GANX

Should you buy Neuphoria Therapeutics stock or one of its competitors? Neuphoria Therapeutics's main competitors and comparable companies include Yarrow Bioscience (YARW), Citius Oncology (CTOR), Telomir Pharmaceuticals (TELO), Sera Prognostics (SERA), and Gain Therapeutics (GANX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Neuphoria Therapeutics compare to Yarrow Bioscience?

Yarrow Bioscience (NASDAQ:YARW) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Neuphoria Therapeutics has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Neuphoria Therapeutics' return on equity of -76.93% beat Yarrow Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%
Neuphoria Therapeutics	N/A	-76.93%	-54.76%

Yarrow Bioscience currently has a consensus target price of $58.00, indicating a potential upside of 114.74%. Neuphoria Therapeutics has a consensus target price of $7.00, indicating a potential upside of 87.67%. Given Yarrow Bioscience's stronger consensus rating and higher probable upside, equities research analysts clearly believe Yarrow Bioscience is more favorable than Neuphoria Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yarrow Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

83.8% of Yarrow Bioscience shares are owned by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 3.0% of Yarrow Bioscience shares are owned by insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Yarrow Bioscience has a beta of 2.01, indicating that its stock price is 101% more volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market.

Neuphoria Therapeutics has higher revenue and earnings than Yarrow Bioscience. Yarrow Bioscience is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yarrow Bioscience	$570K	126.52	-$26.48M	-$14.64	N/A
Neuphoria Therapeutics	$15.65M	1.29	-$370K	-$11.06	N/A

In the previous week, Yarrow Bioscience had 9 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 11 mentions for Yarrow Bioscience and 2 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 0.93 beat Yarrow Bioscience's score of 0.64 indicating that Neuphoria Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Yarrow Bioscience	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neuphoria Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Yarrow Bioscience and Neuphoria Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to Citius Oncology?

Neuphoria Therapeutics (NASDAQ:NEUP) and Citius Oncology (NASDAQ:CTOR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 70.5% of Citius Oncology shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by company insiders. Comparatively, 9.8% of Citius Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Neuphoria Therapeutics had 1 more articles in the media than Citius Oncology. MarketBeat recorded 2 mentions for Neuphoria Therapeutics and 1 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 1.87 beat Neuphoria Therapeutics' score of 0.93 indicating that Citius Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Neuphoria Therapeutics	Positive
Citius Oncology	Very Positive

Neuphoria Therapeutics currently has a consensus target price of $7.00, indicating a potential upside of 87.67%. Citius Oncology has a consensus target price of $6.00, indicating a potential upside of 553.95%. Given Citius Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Citius Oncology is more favorable than Neuphoria Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Neuphoria Therapeutics has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.52, meaning that its share price is 252% more volatile than the broader market.

Neuphoria Therapeutics has higher revenue and earnings than Citius Oncology. Citius Oncology is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$15.65M	1.29	-$370K	-$11.06	N/A
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A

Neuphoria Therapeutics' return on equity of -76.93% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-76.93%	-54.76%
Citius Oncology	N/A	-102.98%	-43.49%

Summary

Citius Oncology beats Neuphoria Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to Telomir Pharmaceuticals?

Neuphoria Therapeutics (NASDAQ:NEUP) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Neuphoria Therapeutics' return on equity of -76.93% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-76.93%	-54.76%
Telomir Pharmaceuticals	N/A	-102.70%	-90.75%

Neuphoria Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market.

Neuphoria Therapeutics presently has a consensus price target of $7.00, suggesting a potential upside of 87.67%. Given Neuphoria Therapeutics' higher probable upside, research analysts plainly believe Neuphoria Therapeutics is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

15.9% of Neuphoria Therapeutics shares are held by institutional investors. 1.5% of Neuphoria Therapeutics shares are held by company insiders. Comparatively, 16.4% of Telomir Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Neuphoria Therapeutics has higher revenue and earnings than Telomir Pharmaceuticals. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$15.65M	1.29	-$370K	-$11.06	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.91	N/A

In the previous week, Neuphoria Therapeutics had 1 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 2 mentions for Neuphoria Therapeutics and 1 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 1.87 beat Neuphoria Therapeutics' score of 0.93 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Neuphoria Therapeutics	Positive
Telomir Pharmaceuticals	Very Positive

Summary

Neuphoria Therapeutics beats Telomir Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to Sera Prognostics?

Neuphoria Therapeutics (NASDAQ:NEUP) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

Neuphoria Therapeutics has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

Neuphoria Therapeutics currently has a consensus target price of $7.00, indicating a potential upside of 87.67%. Sera Prognostics has a consensus target price of $5.50, indicating a potential upside of 170.94%. Given Sera Prognostics' stronger consensus rating and higher possible upside, analysts plainly believe Sera Prognostics is more favorable than Neuphoria Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Neuphoria Therapeutics has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat Neuphoria Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-76.93%	-54.76%
Sera Prognostics	-47,475.72%	-46.71%	-34.06%

Neuphoria Therapeutics has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$15.65M	1.29	-$370K	-$11.06	N/A
Sera Prognostics	$80K	1,001.04	-$31.93M	-$0.67	N/A

In the previous week, Sera Prognostics had 8 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 10 mentions for Sera Prognostics and 2 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 0.93 beat Sera Prognostics' score of 0.44 indicating that Neuphoria Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuphoria Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sera Prognostics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Sera Prognostics beats Neuphoria Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by company insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Gain Therapeutics had 1 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 3 mentions for Gain Therapeutics and 2 mentions for Neuphoria Therapeutics. Gain Therapeutics' average media sentiment score of 1.15 beat Neuphoria Therapeutics' score of 0.93 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neuphoria Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neuphoria Therapeutics has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,527.40	-$20.16M	-$0.50	N/A
Neuphoria Therapeutics	$15.65M	1.29	-$370K	-$11.06	N/A

Gain Therapeutics currently has a consensus price target of $7.50, indicating a potential upside of 328.57%. Neuphoria Therapeutics has a consensus price target of $7.00, indicating a potential upside of 87.67%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Gain Therapeutics is more favorable than Neuphoria Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Neuphoria Therapeutics' return on equity of -76.93% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-161.59%	-118.36%
Neuphoria Therapeutics	N/A	-76.93%	-54.76%

Gain Therapeutics has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market.

Summary

Gain Therapeutics beats Neuphoria Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Neuphoria Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEUP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NEUP vs. The Competition

Export

Metric	Neuphoria Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$20.16M	$3.86B	$7.16B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-0.34	14.18	274.94	25.33
Price / Sales	1.29	1,378.88	633.80	90.72
Price / Cash	23.93	43.64	28.42	34.96
Price / Book	0.37	15.12	10.33	6.21
Net Income	-$370K	-$22.86M	$3.50B	$358.54M
7 Day Performance	-1.06%	-4.34%	-3.32%	-2.35%
1 Month Performance	-2.61%	0.54%	-0.53%	-3.23%
1 Year Performance	-71.33%	40.74%	23.51%	8.79%

Neuphoria Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NEUP Neuphoria Therapeutics	2.1396 of 5 stars	$3.73 flat	$7.00 +87.7%	-71.3%	$20.16M	$15.65M	N/A	N/A	News Coverage
YARW Yarrow Bioscience	2.5225 of 5 stars	$30.21 +4.7%	$58.00 +92.0%	N/A	$80.65M	$570K	N/A	30	News Coverage Short Interest Increase Gap Down
CTOR Citius Oncology	2.0122 of 5 stars	$0.86 +8.6%	$6.00 +597.7%	-52.0%	$79.96M	N/A	N/A	N/A	Positive News Gap Down
TELO Telomir Pharmaceuticals	0.4628 of 5 stars	$1.16 flat	N/A	-14.0%	$79.78M	N/A	N/A	1
SERA Sera Prognostics	2.4496 of 5 stars	$2.02 +2.0%	$5.50 +172.3%	-34.5%	$79.69M	$70K	N/A	120	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NEUP) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neuphoria Therapeutics (NEUP) Competitors

NEUP vs. YARW, CTOR, TELO, SERA, and GANX

How does Neuphoria Therapeutics compare to Yarrow Bioscience?

Summary

How does Neuphoria Therapeutics compare to Citius Oncology?

Summary

How does Neuphoria Therapeutics compare to Telomir Pharmaceuticals?

Summary

How does Neuphoria Therapeutics compare to Sera Prognostics?

Summary

How does Neuphoria Therapeutics compare to Gain Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEUP vs. The Competition

Neuphoria Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neuphoria Therapeutics (NEUP) Competitors

NEUP vs. YARW, CTOR, TELO, SERA, and GANX

How does Neuphoria Therapeutics compare to Yarrow Bioscience?

Is YARW or NEUP more profitable?

Do analysts recommend YARW or NEUP?

Do institutionals and insiders have more ownership in YARW or NEUP?

Which has more volatility and risk, YARW or NEUP?

Which has stronger valuation & earnings, YARW or NEUP?

Does the media refer more to YARW or NEUP?

Summary

How does Neuphoria Therapeutics compare to Citius Oncology?

Do institutionals & insiders believe in NEUP or CTOR?

Does the media prefer NEUP or CTOR?

Do analysts prefer NEUP or CTOR?

Which has more volatility and risk, NEUP or CTOR?

Which has higher valuation and earnings, NEUP or CTOR?

Is NEUP or CTOR more profitable?

Summary

How does Neuphoria Therapeutics compare to Telomir Pharmaceuticals?

Is NEUP or TELO more profitable?

Which has more risk & volatility, NEUP or TELO?

Do analysts rate NEUP or TELO?

Do institutionals and insiders hold more shares of NEUP or TELO?

Which has higher valuation & earnings, NEUP or TELO?

Does the media prefer NEUP or TELO?

Summary

How does Neuphoria Therapeutics compare to Sera Prognostics?

Which has more volatility and risk, NEUP or SERA?

Do analysts rate NEUP or SERA?

Is NEUP or SERA more profitable?

Which has preferable valuation and earnings, NEUP or SERA?

Does the media refer more to NEUP or SERA?

Do insiders & institutionals have more ownership in NEUP or SERA?

Summary

How does Neuphoria Therapeutics compare to Gain Therapeutics?

Do insiders and institutionals have more ownership in GANX or NEUP?

Does the media refer more to GANX or NEUP?

Which has preferable earnings and valuation, GANX or NEUP?

Do analysts prefer GANX or NEUP?

Is GANX or NEUP more profitable?

Which has more risk and volatility, GANX or NEUP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEUP vs. The Competition

Neuphoria Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools